174689-39-5

174689-39-5 structure

Name: SR59230A
Chemical Name: SR 59230A hydrochloride,1-(2-Ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanolhydrochloride
CAS Number: 174689-39-5
Molecular Formula: C₂₃H₂₉NO₆
Molecular Weight: 415.47900
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2016-03-10 18:55:16
Modify Date: 2024-01-06 11:23:08
SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist[1] with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively[2].

Name	SR 59230A hydrochloride,1-(2-Ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanolhydrochloride
Synonyms	3-(2-Ethylphenoxy)-1-[[(1S)-1,2,3,4-tetrahydronaphth-1-yl]amino]-(2S)-2-propanol oxalate salt

Description	SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist[1] with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively[2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Metabolic Disease
Target	IC50: 40 nM (β3 receptor), 408 nM ((β1 receptor), 648 nM (β2 receptor)[2]
In Vitro	SR59230A (100 nM-50 μM; 24 hours) is able to reduce cell viability in a dose-dependent manner in Neuro-2A, BE(2)C and SK-N-BE(2) NB cell lines[3]. Cell Viability Assay[3] Cell Line: Three different neuroblastoma (NB) cell lines, one murine (Neuro-2A) and two human (SK-N-BE(2), BE(2)C) Concentration: 100 nM, 1 μM, 5 μM, 10 μM, and 50 μM Incubation Time: 24 hours Result: Reduced cell viability in a dose-dependent manner, with significant effect at a concentration limit over 1 µM for Neuro-2A cells and 5 µM for SK-N-BE(2) and BE(2)C).
In Vivo	MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA[4]. Animal Model: Male C-57BL6J wild-type mice (22-35 g)[4] Dosage: 0.5 or 5 mg/kg Administration: Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg). Result: Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism.
References	[1]. Nisoli E, et al. Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes.Mol Pharmacol. 1996 Jan;49(1):7-14. [2]. Kanzler SA, et al. Involvement of β3-adrenergic receptors in the control of food intake in rats.Braz J Med Biol Res. 2011 Nov;44(11):1141-7. [3]. Bruno G, et al. β3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P2 modulation.Oncogene. 2020 Jan;39(2):368-384. [4]. Bexis S, et al. Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol. 2009 Sep;158(1):259-66.

Boiling Point	542.6ºC at 760mmHg
Molecular Formula	C₂₃H₂₉NO₆
Molecular Weight	415.47900
Flash Point	281.9ºC
Exact Mass	415.19900
PSA	116.09000
LogP	3.20240
Vapour Pressure	1.27E-11mmHg at 25°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Risk Phrases	22-24/25
RIDADR	NONH for all modes of transport

174689-39-5	1135278-41-9
96574-32-2	1506915-69-0
1260169-20-7	1531661-78-5
112749-48-1	112748-47-7
1781878-66-7	1784212-75-4
1368383-37-2	1782564-79-7